Puma Biotechnology Dirección
Dirección controles de criterios 4/4
El CEO de Puma Biotechnology es Alan Auerbach , nombrado en Sep 2010, tiene una permanencia de 15.83 años. compensación anual total es $3.06M, compuesta por 30.4% salario y 69.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 13.93% de las acciones de la empresa, por valor de $56.74M. La antigüedad media del equipo directivo y de la junta directiva es de 8.1 años y 9.7 años, respectivamente.
Información clave
Alan Auerbach
Chief Executive Officer (CEO)
US$3.1m
Compensación total
| Porcentaje del salario del CEO | 30.41% |
| Permanencia del CEO | 15.8yrs |
| Participación del CEO | 13.9% |
| Permanencia media de la dirección | 8.1yrs |
| Promedio de permanencia en la Junta Directiva | 9.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Jun 06
PBYI: 2026 Revenue Guidance Will Likely Still Fail To Justify Pricing
Analysts have kept their $5.00 price target on Puma Biotechnology broadly aligned with prior estimates, reflecting only small adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E inputs in their valuation work. What's in the News Puma Biotechnology raised full year 2026 guidance, now expecting total revenue of US$222 million to US$229 million and net income of US$16 million to US$19 million, citing increased demand for NERLYNX.Actualización de narrativa • May 19
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology to reflect updated views on fair value at $5.00. This change is accompanied by revised assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple.Artículo de análisis • May 15
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) earnings announcement last week didn't impress shareholders. However, our...Artículo de análisis • May 11
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
A week ago, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) came out with a strong set of first-quarter numbers that could...Actualización de narrativa • Apr 28
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology slightly, with the updated fair value moving to $5.00. This reflects refreshed views on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions.Actualización de narrativa • Apr 11
PBYI: 2026 Profitability Guidance Will Likely Fail To Support Current Pricing
Analysts have slightly adjusted their price target on Puma Biotechnology, keeping fair value around $5.00 while fine tuning inputs such as discount rate, revenue growth, profit margin, and future P/E to reflect updated assumptions about the company’s risk profile and earnings potential. What's in the News Puma Biotechnology issued new earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million, with an expected net loss of US$8 million to US$10 million (company guidance).Actualización de narrativa • Mar 28
PBYI: 2026 Guidance Will Likely Fail To Justify Current Pricing
Analysts have modestly adjusted their price target on Puma Biotechnology, reflecting small refinements to assumptions around the discount rate, revenue growth, profit margins, and forward P/E rather than a major shift in the outlook. What's in the News Puma Biotechnology issued earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million (Key Developments).Actualización de narrativa • Mar 13
PBYI: Index Inclusion Will Likely Fail To Offset Weak Revenue Outlook
Analysts have trimmed their price target on Puma Biotechnology to $5.00 from $5.00 in response to updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E. These changes leave the fair value estimate effectively unchanged.Actualización de narrativa • Feb 26
PBYI: Index Addition And Refined Assumptions Will Still Limit Upside Potential
Analysts have adjusted their price target on Puma Biotechnology to reflect an updated fair value of $5.00, a slightly lower discount rate of 7.25%, almost unchanged revenue growth at about 97%, a stable profit margin near 11.02%, and a marginally different future P/E of roughly 13.33x, indicating a largely intact valuation framework with only fine tuning to their assumptions. What's in the News Puma Biotechnology, Inc.Actualización de narrativa • Feb 11
PBYI: Index Inclusion And Higher Multiple Will Likely Fail To Support Upside
Analysts have raised their price target on Puma Biotechnology to $5.00 from $3.50, citing updates to fair value estimates, discount rate assumptions, and expected future P/E levels. What's in the News Puma Biotechnology, Inc.Actualización de narrativa • Jan 26
PBYI: Higher 2025 Guidance And Index Addition Will Not Sustain Current Optimism
Analysts have slightly adjusted their price target on Puma Biotechnology, citing modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these changes translate into a small refinement in estimated fair value rather than a major reset in outlook.
Actualización de narrativa • Jan 12
PBYI: Higher 2025 Guidance And Index Inclusion Will Still Look Overpriced
Analysts have lifted their price targets on Puma Biotechnology, citing updates to their models that reflect a fair value estimate of $5.00, adjusted discount rates, revised revenue growth assumptions of about 1% instead of a 3% decline, higher projected profit margins of around 10% compared with about 3%, and a lower assumed future P/E multiple near 14 versus about 37. What's in the News Puma Biotechnology, Inc.Actualización de narrativa • Dec 26
PBYI: Raised 2025 Guidance Will Still Fail To Support Current Optimism
Analysts have modestly trimmed their price target on Puma Biotechnology to reflect a slightly lower future earnings multiple, even as estimates for fair value and long term growth remain largely unchanged. What's in the News Puma Biotechnology has been added to the NASDAQ Biotechnology Index, increasing its visibility among biotech-focused investors (index announcement).Actualización de narrativa • Dec 12
PBYI: 2025 Revenue Guidance Will Fail To Justify Current Optimism
Analysts have modestly adjusted their price target on Puma Biotechnology higher, now seeing slightly improved valuation support in light of stable fair value estimates and marginally lower perceived risk in the companys long term outlook. What's in the News Puma Biotechnology issued new fourth quarter 2025 guidance, projecting total revenue between $67 million and $70 million and net income of $9 million to $11 million (company guidance).Artículo de análisis • Dec 09
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Actualización de narrativa • Nov 27
PBYI: Rising Discount Rate Will Undermine Earnings Momentum In 2025
Analysts have slightly lowered their price target for Puma Biotechnology, citing marginal revisions in key financial estimates. This resulted in a new target of $3.50 per share, which remains unchanged from the previous assessment.Artículo de análisis • Nov 13
Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit
The market shrugged off Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) solid earnings report. We think that investors might...Seeking Alpha • Nov 10
Puma Biotechnology: Step By Step In Making A Transition
Summary Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise. Read the full article on Seeking AlphaActualización de narrativa • Nov 09
PBYI: Rising Discount Rate And Weak Revenue Outlook Will Pressure Earnings
Analysts have raised their price target for Puma Biotechnology from $3.00 to $3.50, citing improved revenue growth projections and stronger expected profit margins. What's in the News Puma Biotechnology issued new earnings guidance for the fourth quarter of 2025, projecting total revenue between $67 million and $70 million, and net income between $9 million and $11 million (Key Developments).Artículo de análisis • Oct 18
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have continued their recent momentum with a 26% gain in the last month...Artículo de análisis • Sep 11
Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Aug 12
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market
NasdaqGS:PBYI 1 Year Share Price vs Fair Value Explore Puma Biotechnology's Fair Values from the Community and select...Artículo de análisis • Aug 09
We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • May 20
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shareholders have had their patience rewarded with a 25% share price jump in...Seeking Alpha • Apr 11
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential
Summary Initiate coverage of Puma Biotechnology with a Hold rating due to limited near-term upside, competitive landscape, and uncertain pipeline outlook. NERLYNX adoption is hindered by side effects and competition, while alisertib is still in early development with modest expectations. Puma's cash runway may extend several years, but that could change with faltering revenues for NERLYNX, new drug additions, or other unforeseen pipeline developments. Legal issues and competitive pressures contribute to the cautious outlook, with no clear signs of growth or turnaround. Read the full article on Seeking AlphaArtículo de análisis • Mar 10
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have had a really impressive month, gaining 26% after a shaky period...
Nueva narrativa • Feb 09
Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains
Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.Artículo de análisis • Jan 14
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Puma Biotechnology, Inc. ( NASDAQ:PBYI ) is...Seeking Alpha • Dec 16
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Summary Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stable financially. Alisertib shows early efficacy signals, with phase 2 trials ongoing, but its future success remains uncertain. Despite market skepticism, I maintain a "Buy" sentiment due to PBYI's favorable financial status and potential growth from alisertib. Read the full article on Seeking AlphaArtículo de análisis • Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
When companies post strong earnings, the stock generally performs well, just like Puma Biotechnology, Inc.'s...Artículo de análisis • Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 26% in...Artículo de análisis • Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 25% in...Artículo de análisis • Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$24m |
| Dec 31 2025 | US$3m | US$931k | US$31m |
| Sep 30 2025 | n/a | n/a | US$37m |
| Jun 30 2025 | n/a | n/a | US$48m |
| Mar 31 2025 | n/a | n/a | US$38m |
| Dec 31 2024 | US$4m | US$904k | US$30m |
| Sep 30 2024 | n/a | n/a | US$23m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | US$15m |
| Dec 31 2023 | US$3m | US$878k | US$22m |
| Sep 30 2023 | n/a | n/a | US$4m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | US$5m |
| Dec 31 2022 | US$3m | US$852k | US$2k |
| Sep 30 2022 | n/a | n/a | US$10m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$18m | US$827k | -US$29m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$27m |
| Dec 31 2020 | US$4m | US$834k | -US$60m |
| Sep 30 2020 | n/a | n/a | -US$56m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$4m | US$780k | -US$76m |
Compensación vs. Mercado: La compensación total ($USD3.06M) de Alan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.41M).
Compensación vs. Ingresos: La compensación de Alan ha sido consistente con los resultados de la empresa en el último año.
CEO
Alan Auerbach (56 yo)
15.8yrs
Permanencia
US$3,062,337
Compensación
Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman since October 4, 2011 and serves as its Chief Executive Officer, President and Secretary since September...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 15.8yrs | US$3.06m | 13.93% $ 56.7m | |
| CFO & Principal Accounting Officer | 7.7yrs | US$1.24m | 0.35% $ 1.4m | |
| Chief Regulatory Affairs | 8.5yrs | US$1.06m | 0.29% $ 1.2m | |
| Chief Accounting Officer | no data | sin datos | sin datos | |
| Senior Director of Investor Relations | 14.7yrs | sin datos | sin datos | |
| Senior Vice President of Marketing | 5.1yrs | sin datos | sin datos | |
| Senior Vice President of Sales | no data | sin datos | sin datos | |
| Senior Vice President of Clinical Operations | no data | sin datos | sin datos | |
| Senior Vice President of Clinical Development | less than a year | sin datos | sin datos | |
| Senior Vice President of Supply Chain & Manufacturing | no data | sin datos | sin datos | |
| Senior Vice President of Quality Assurance | no data | sin datos | sin datos |
8.1yrs
Permanencia media
57.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PBYI es experimentado (8.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 14.8yrs | US$3.06m | 13.93% $ 56.7m | |
| Lead Independent Director | 14.3yrs | US$173.08k | 0.062% $ 250.6k | |
| Independent Director | 8.4yrs | US$158.08k | 0.11% $ 432.0k | |
| Independent Director | 12.8yrs | US$173.08k | 0.065% $ 266.4k | |
| Independent Director | 4yrs | US$153.08k | 0.082% $ 334.8k | |
| Independent Director | 10.9yrs | US$165.58k | sin datos | |
| Independent Director | 5yrs | US$155.58k | 0.13% $ 510.3k | |
| Independent Director | 6yrs | US$168.08k | 0.17% $ 694.9k |
9.7yrs
Permanencia media
63.5yo
Promedio de edad
Junta con experiencia: La junta directiva de PBYI se considera experimentada (9.7 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/13 08:06 |
| Precio de las acciones al final del día | 2026/07/10 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Puma Biotechnology, Inc. está cubierta por 13 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Paul Choi | Goldman Sachs |